TG Therapeutics (NASDAQ:TGTX) Rating Reiterated by HC Wainwright

TG Therapeutics (NASDAQ:TGTX)‘s stock had its “buy” rating reaffirmed by research analysts at HC Wainwright in a research report issued on Thursday, Benzinga reports. They presently have a $45.00 price objective on the biopharmaceutical company’s stock. HC Wainwright’s target price suggests a potential upside of 215.79% from the stock’s previous close.

TGTX has been the subject of a number of other reports. StockNews.com lowered shares of TG Therapeutics from a “buy” rating to a “hold” rating in a research report on Saturday, February 24th. B. Riley raised their target price on shares of TG Therapeutics from $24.00 to $29.00 and gave the company a “buy” rating in a research note on Monday, February 5th. Finally, The Goldman Sachs Group raised their target price on shares of TG Therapeutics from $12.00 to $13.00 and gave the company a “neutral” rating in a research note on Thursday, February 29th. Two equities research analysts have rated the stock with a hold rating and five have given a buy rating to the company’s stock. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average price target of $29.00.

TG Therapeutics Price Performance

Shares of TGTX stock traded up $0.43 during trading hours on Thursday, reaching $14.25. The stock had a trading volume of 1,905,647 shares, compared to its average volume of 4,174,303. The stock’s fifty day simple moving average is $15.14 and its 200 day simple moving average is $13.87. The company has a current ratio of 5.92, a quick ratio of 5.18 and a debt-to-equity ratio of 0.62. TG Therapeutics has a 12 month low of $6.46 and a 12 month high of $35.67. The firm has a market capitalization of $2.20 billion, a PE ratio of 710.86 and a beta of 2.30.

TG Therapeutics (NASDAQ:TGTX) last released its quarterly earnings data on Wednesday, February 28th. The biopharmaceutical company reported ($0.09) EPS for the quarter, beating analysts’ consensus estimates of ($0.12) by $0.03. TG Therapeutics had a net margin of 5.42% and a return on equity of 12.89%. The company had revenue of $43.97 million during the quarter, compared to analyst estimates of $40.06 million. During the same period last year, the business earned ($0.39) earnings per share. On average, equities research analysts predict that TG Therapeutics will post -0.12 EPS for the current year.

Insider Activity at TG Therapeutics

In other TG Therapeutics news, Director Laurence N. Charney sold 22,000 shares of TG Therapeutics stock in a transaction that occurred on Tuesday, March 12th. The shares were sold at an average price of $15.97, for a total transaction of $351,340.00. Following the transaction, the director now directly owns 215,229 shares of the company’s stock, valued at $3,437,207.13. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. 9.20% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

Several large investors have recently made changes to their positions in TGTX. Pingora Partners LLC purchased a new position in shares of TG Therapeutics during the fourth quarter worth approximately $27,000. PNC Financial Services Group Inc. increased its stake in shares of TG Therapeutics by 131.7% in the third quarter. PNC Financial Services Group Inc. now owns 3,543 shares of the biopharmaceutical company’s stock worth $30,000 after buying an additional 2,014 shares during the period. Macquarie Group Ltd. increased its stake in shares of TG Therapeutics by 102.3% in the second quarter. Macquarie Group Ltd. now owns 10,190 shares of the biopharmaceutical company’s stock worth $43,000 after buying an additional 5,152 shares during the period. Coppell Advisory Solutions LLC purchased a new position in shares of TG Therapeutics in the second quarter worth $46,000. Finally, KBC Group NV purchased a new position in shares of TG Therapeutics in the fourth quarter worth $54,000. 58.58% of the stock is owned by hedge funds and other institutional investors.

TG Therapeutics Company Profile

TG Therapeutics, Inc, a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults.